Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- Q14653 Q 14653 S386 S396 S 386A 396A 386 396 IRF-3 DRAF 1 IKK IFN? HEK-293 TBK IFN?
- Product Overview:
IFR3 (S386A, S396A mutant; human recombinant) contains amino acids corresponding to human IRF3 (Item No. 22811) with alanine substituted for serine at positions 386 and 396. Interferon regulatory factor 3 (IRF3) is a member of the IRF family that plays a crucial role in activation of innate immunity and inflammation in response to viral infection, functioning as a molecular switch for antiviral activity.{39335,39336,39337,39338,39339} Double-stranded RNA generated during a viral infection leads to IRF3 activation through serine/threonine phosphorylation by TBK1 (Item No. 22817) or IKK? (IKBKE) kinases, which induces a conformational change leading to its dimerization, nuclear localization, and association with CREB binding protein (CREBBP)/p300.{39335,39336,39338,39334} The complex formed by this association, known as DRAF1, activates transcription of interferon ? (IFN-?) and IFN-? as well as other IFN-induced genes, which play a critical role in the type 1 IFN-dependent immune response.{39335,39339,39334} Various serine residues have been implicated in IRF3 activation, including S386 and S396.{35291} TBK1 and IKK? phosphorylation of IRF3 is decreased when serine is replaced with alanine at positions 396, 398, 402, and 405 and with threonine at position 404. Phosphorylation of S386 is essential for IRF3 oligomerization and binding to p300, and phosphorylation of S396, T390, and either S385 or S386 occurs following Sendai viral infection in HEK293 cells.{35292,35293}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.